130 related articles for article (PubMed ID: 23551354)
21. [A transdermal patch of rivastigmine (Exelon)].
Salmon E
Rev Med Liege; 2008 Sep; 63(9):570-1. PubMed ID: 19051514
[TBL] [Abstract][Full Text] [Related]
22. Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.
Dhillon S
Drugs Aging; 2011 Nov; 28(11):927-30. PubMed ID: 22054233
[TBL] [Abstract][Full Text] [Related]
23. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
Reñé R; Ricart J; Hernández B;
Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
[TBL] [Abstract][Full Text] [Related]
24. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
[TBL] [Abstract][Full Text] [Related]
26. Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease.
Servello A; Ettorre E; Cacciafesta M
Panminerva Med; 2017 Sep; 59(3):275-277. PubMed ID: 28665099
[No Abstract] [Full Text] [Related]
27. Rivastigmine exposure provided by a transdermal patch versus capsules.
Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
[TBL] [Abstract][Full Text] [Related]
28. Which rivastigmine formula is better for heart in elderly patients with Alzheimer's disease: oral or patch?
Isik AT; Soysal P; Yay A
Am J Alzheimers Dis Other Demen; 2014 Dec; 29(8):735-8. PubMed ID: 24867375
[TBL] [Abstract][Full Text] [Related]
29. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Dhillon S
Drugs; 2011 Jun; 71(9):1209-31. PubMed ID: 21711064
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
Blesa González R; Boada Rovira M; Martínez Parra C; Gil-Saladié D; Almagro CA; Gobartt Vázquez AL;
Neurologia; 2011 Jun; 26(5):262-71. PubMed ID: 21227548
[TBL] [Abstract][Full Text] [Related]
31. Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study.
Tian H; Abouzaid S; Chen W; Kahler KH; Kim E
Alzheimer Dis Assoc Disord; 2013; 27(2):182-6. PubMed ID: 22892648
[TBL] [Abstract][Full Text] [Related]
32. Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.
Amanatkar HR; Grossberg GT
Expert Rev Neurother; 2014 Oct; 14(10):1119-25. PubMed ID: 25201245
[TBL] [Abstract][Full Text] [Related]
33. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
Yang LP; Keating GM
CNS Drugs; 2007; 21(11):957-65. PubMed ID: 17927299
[No Abstract] [Full Text] [Related]
34. Acute dystonic reaction with rivastigmine.
Dhikav V; Anand KS
Int Psychogeriatr; 2013 Aug; 25(8):1385-6. PubMed ID: 23561545
[TBL] [Abstract][Full Text] [Related]
35. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
37. Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial.
Aguiar P; Monteiro L; Feres A; Gomes I; Melo A
Curr Alzheimer Res; 2014; 11(6):532-7. PubMed ID: 24938502
[TBL] [Abstract][Full Text] [Related]
38. Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study.
Segers K; Cytryn E; Surquin M
J Clin Psychopharmacol; 2012 Jun; 32(3):412-5. PubMed ID: 22544007
[TBL] [Abstract][Full Text] [Related]
39. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
[TBL] [Abstract][Full Text] [Related]
40. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
